BR112018011073A2 - anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização - Google Patents

anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização

Info

Publication number
BR112018011073A2
BR112018011073A2 BR112018011073A BR112018011073A BR112018011073A2 BR 112018011073 A2 BR112018011073 A2 BR 112018011073A2 BR 112018011073 A BR112018011073 A BR 112018011073A BR 112018011073 A BR112018011073 A BR 112018011073A BR 112018011073 A2 BR112018011073 A2 BR 112018011073A2
Authority
BR
Brazil
Prior art keywords
methods
myostatin antibodies
polypeptides containing
containing variant
nucleic acids
Prior art date
Application number
BR112018011073A
Other languages
English (en)
Inventor
Katada Hitoshi
Kuramochi Taichi
Igawa Tomoyuki
Hori Yuji
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112018011073A2 publication Critical patent/BR112018011073A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a anticorpos antimiostatina e métodos de produção e utilização dos mesmos. os ácidos nucleicos que codificam os anticorpos antimiostatina e células hospedeiras compreendendo os ácidos nucleicos também são providos. a descrição também provê polipeptídeos contendo uma região fc variante e métodos de produção e utilização dos mesmos. os ácidos nucleicos que codificam os polipeptídeos e células hospedeiras compreendendo os ácidos nucleicos também são providos.
BR112018011073A 2015-12-18 2016-12-16 anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização BR112018011073A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
PCT/JP2016/087487 WO2017104783A1 (en) 2015-12-18 2016-12-16 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Publications (1)

Publication Number Publication Date
BR112018011073A2 true BR112018011073A2 (pt) 2018-11-21

Family

ID=59011957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011073A BR112018011073A2 (pt) 2015-12-18 2016-12-16 anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização

Country Status (16)

Country Link
EP (1) EP3390443A4 (pt)
JP (4) JP6142069B1 (pt)
KR (4) KR102501335B1 (pt)
CN (2) CN115028721A (pt)
AR (1) AR107078A1 (pt)
AU (1) AU2016372934B2 (pt)
BR (1) BR112018011073A2 (pt)
CA (1) CA3002422C (pt)
EA (1) EA201891420A1 (pt)
HK (1) HK1254755A1 (pt)
MX (1) MX2018007145A (pt)
MY (1) MY189425A (pt)
PH (1) PH12018501280A1 (pt)
SG (2) SG10201707267RA (pt)
TW (3) TWI749057B (pt)
WO (1) WO2017104783A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
ES2563483T3 (es) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN107964042B (zh) 2012-05-30 2022-04-19 中外制药株式会社 靶组织特异性抗原结合分子
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
KR102284503B1 (ko) 2013-12-04 2021-07-30 추가이 세이야쿠 가부시키가이샤 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
KR102501335B1 (ko) * 2015-12-18 2023-02-17 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
TWI611811B (zh) * 2016-06-17 2018-01-21 中外製藥股份有限公司 抗肌抑素抗體及使用方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
CN110352074B (zh) 2017-02-28 2024-07-16 思进股份有限公司 用于偶联的半胱氨酸突变抗体
CN112839960A (zh) 2018-08-10 2021-05-25 中外制药株式会社 抗cd137抗原结合分子及其应用
CA3136398A1 (en) 2019-04-10 2020-10-15 Chugai Seiyaku Kabushiki Kaisha Method for purifying fc region-modified antibody
JP2022548043A (ja) * 2019-09-13 2022-11-16 アドマーレ セラピューティクス ソサイエティ 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
WO2023187022A1 (en) 2022-04-01 2023-10-05 F. Hoffmann-La Roche Ag New treatment for facioscapulohumeral muscular dystrophy (fshd)
US11780910B1 (en) 2022-05-02 2023-10-10 Novo Nordisk A/S Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
US20240173325A1 (en) 2022-10-14 2024-05-30 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2005289685B2 (en) * 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5058261B2 (ja) * 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
ES2563483T3 (es) * 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
MY172730A (en) * 2012-03-16 2019-12-11 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
US9540449B2 (en) * 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
CA2882272C (en) * 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
SG10201800800YA (en) * 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
SG11201600212VA (en) * 2013-08-14 2016-02-26 Novartis Ag Methods of treating sporadic inclusion body myositis
EP3215175A4 (en) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
SG11201700841QA (en) * 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102501335B1 (ko) 2015-12-18 2023-02-17 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법

Also Published As

Publication number Publication date
KR20240058997A (ko) 2024-05-03
JP7053164B2 (ja) 2022-04-12
CN108473562A (zh) 2018-08-31
KR20230027321A (ko) 2023-02-27
CA3002422A1 (en) 2017-06-22
WO2017104783A1 (en) 2017-06-22
CN108473562B (zh) 2022-06-17
KR102501335B1 (ko) 2023-02-17
AU2016372934A1 (en) 2018-05-10
TW202231662A (zh) 2022-08-16
KR20180085711A (ko) 2018-07-27
RU2018125431A3 (pt) 2020-07-06
RU2018125431A (ru) 2020-01-20
JP6142069B1 (ja) 2017-06-07
EP3390443A4 (en) 2019-11-13
MY189425A (en) 2022-02-10
CA3002422C (en) 2024-04-16
SG11201610812WA (en) 2017-07-28
MX2018007145A (es) 2018-08-15
TWI749057B (zh) 2021-12-11
TW201726718A (zh) 2017-08-01
TW201808992A (zh) 2018-03-16
CN115028721A (zh) 2022-09-09
JP2017112997A (ja) 2017-06-29
KR101820637B1 (ko) 2018-01-19
PH12018501280A1 (en) 2019-01-28
AR107078A1 (es) 2018-03-21
JP2017148069A (ja) 2017-08-31
EA201891420A1 (ru) 2019-02-28
KR20170085028A (ko) 2017-07-21
AU2016372934B2 (en) 2023-10-05
HK1254755A1 (zh) 2019-07-26
TWI605057B (zh) 2017-11-11
JP2022097485A (ja) 2022-06-30
EP3390443A1 (en) 2018-10-24
JP2024023427A (ja) 2024-02-21
SG10201707267RA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018007017A2 (pt) polipeptídeos
BR112019012343A2 (pt) anticorpos il-11ra
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
BR112017021289A2 (pt) anticorpos anti-c1s humanizados e métodos de uso dos mesmos
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
BR112017004495A2 (pt) variantes de celobiohidrolase e polinucleotídeos codificando as mesmas
BR112017003263A2 (pt) anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
BR112016019390A2 (pt) proteínas de fusão uti
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112016027884A2 (pt) variante de xilanase da família 11 de gh, polinucleotídeo, construção de ácido nucleico, vetor de expressão, célula hospedeira, e, métodos de produção de uma variante de xilanase da família 11 de gh e de degradação de um material

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]